Certolizumab pegol

培塞利珠单抗

Report date: 2022/12/27 14:13:48

Base Information

Drug NameCertolizumab pegol
Drug Alias NameSimziya赛妥珠单抗妥珠单抗CIMZIA AutoClicks Prefilled Pencertolizumabum pegolum +[17] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic Arthritis +[18] 
Global Approved IndicationsCrohn DiseaseArthritis, Rheumatoid
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryUnited States
Original Approved Date2008/04/22
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active CompaniesUcb Biopharma SrlUcb IncUcb Pharma +[8] 
Inactive CompaniesUcb CelltechUcb Biopharma SprlUcb Manufacturing Inc +[13] 
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic Arthritis +[10] 
Inactive IndicationsPalmoplantar pustulosisGeneralised pustular psoriasisErythrodermic psoriasis +[8] 

Other Information

ATC CodeL04AB05
Related LinksWikipediaDrugBankKEGG